kabutan

KYORIN Pharmaceutical Co.,Ltd.(4569) Summary

4569
TSE Prime
KYORIN Pharmaceutical Co.,Ltd.
1,478
JPY
+9
(+0.61%)
Dec 5, 12:45 pm JST
9.52
USD
Dec 4, 10:45 pm EST
Result
PTS
outside of trading hours
1,474.6
Dec 5, 12:35 pm JST
Summary Chart Historical News Financial Result
PER
17.6
PBR
0.62
Yield
3.86%
Margin Trading Ratio
68.88
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
1,467 JPY 9.45 USD
Previous Close Dec 4
1,469 JPY 9.45 USD
High Dec 5, 9:36 am
1,495 JPY 9.63 USD
Low Dec 5, 9:00 am
1,467 JPY 9.45 USD
Volume
45,600
Trading Value
0.07B JPY 0.44M USD
VWAP
1480.74 JPY 9.55 USD
Minimum Trading Value
147,800 JPY 952 USD
Market Cap
0.09T JPY 0.57B USD
Number of Trades
179
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Mid
1-Year Average
353
1-Year High Mar 5, 2025
5,734
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 11,000 133,800 12.16
Nov 21, 2025 12,200 136,700 11.20
Nov 14, 2025 23,500 154,800 6.59
Nov 7, 2025 16,700 142,600 8.54
Oct 31, 2025 19,400 143,300 7.39
Company Profile
KYORIN Pharmaceutical Co., Ltd. is a mid-tier pharmaceutical company. Its main products include asthma medications and expectorants. The company also produces generic drugs and gastrointestinal medicines.
Sector
Pharmaceuticals
KYORIN Pharmaceutical Co., Ltd. primarily engages in the manufacture and sale of pharmaceuticals. The company focuses on prescription drugs such as asthma medications and expectorants, while also having a track record in generic drugs and COVID-19 detection reagents. With manufacturing and sales companies within its group, KYORIN has established an integrated business structure. The company procures some pharmaceutical raw materials from its affiliated companies. In recent years, KYORIN has undergone group restructuring, including the absorption and merger of wholly-owned subsidiaries, to improve management efficiency and accelerate decision-making processes. While adapting to changing medical needs, the company is also concentrating on developing new drugs using its proprietary drug discovery technologies.